全文获取类型
收费全文 | 4322篇 |
免费 | 415篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 206篇 |
妇产科学 | 111篇 |
基础医学 | 689篇 |
口腔科学 | 109篇 |
临床医学 | 362篇 |
内科学 | 908篇 |
皮肤病学 | 86篇 |
神经病学 | 260篇 |
特种医学 | 294篇 |
外科学 | 645篇 |
综合类 | 53篇 |
一般理论 | 1篇 |
预防医学 | 320篇 |
眼科学 | 64篇 |
药学 | 296篇 |
中国医学 | 7篇 |
肿瘤学 | 335篇 |
出版年
2023年 | 27篇 |
2022年 | 30篇 |
2021年 | 50篇 |
2020年 | 45篇 |
2019年 | 39篇 |
2018年 | 105篇 |
2017年 | 78篇 |
2016年 | 84篇 |
2015年 | 111篇 |
2014年 | 146篇 |
2013年 | 206篇 |
2012年 | 181篇 |
2011年 | 124篇 |
2010年 | 142篇 |
2009年 | 161篇 |
2008年 | 146篇 |
2007年 | 174篇 |
2006年 | 168篇 |
2005年 | 132篇 |
2004年 | 157篇 |
2003年 | 134篇 |
2002年 | 145篇 |
2001年 | 113篇 |
2000年 | 117篇 |
1999年 | 140篇 |
1998年 | 144篇 |
1997年 | 111篇 |
1996年 | 136篇 |
1995年 | 96篇 |
1994年 | 104篇 |
1993年 | 60篇 |
1992年 | 113篇 |
1991年 | 104篇 |
1990年 | 80篇 |
1989年 | 110篇 |
1988年 | 98篇 |
1987年 | 86篇 |
1986年 | 82篇 |
1985年 | 85篇 |
1984年 | 40篇 |
1983年 | 36篇 |
1982年 | 34篇 |
1981年 | 32篇 |
1980年 | 24篇 |
1979年 | 24篇 |
1977年 | 30篇 |
1976年 | 28篇 |
1975年 | 24篇 |
1973年 | 17篇 |
1969年 | 18篇 |
排序方式: 共有4768条查询结果,搜索用时 15 毫秒
31.
V Dacquet A Varlet R N Tandogan M M Tahon L Fournier F Jehl H Monteil G Bascoulergue 《Clinical orthopaedics and related research》1992,(282):241-249
Teicoplanin-impregnated plaster of Paris beads were made and in vitro release properties were studied. Teicoplanin was released in an initial massive dose, with a rapid decline during the first three days, followed by a slowly declining prolonged release up to 30 days. The release tested by diffusion in gelose and high-performance liquid chromatography was found to be 21.4% and 28.2%, respectively, of the amount theoretically present in the beads. Plaster of Paris is a resorbable, nontoxic biomaterial that has already been used to fill dead spaces in bone and deliver antibiotics in the treatment of chronic osteomyelitis. The addition of teicoplanin, a new antistaphylococcal agent with low known bacterial resistance, is a promising alternative. Follow-up tests in vivo, simulating local conditions of the osteomyelitic bone, are necessary to prove efficacy. 相似文献
32.
33.
34.
35.
M Durdu† S Gökçe‡ M Bagirova§ M Yalaz‡ AM Allahverdiyev§ S Uzun† 《Journal of the European Academy of Dermatology and Venereology》2007,21(2):214-218
OBJECTIVE: Although cutaneous leishmaniasis (CL) occurs mostly in the facial area, periocular involvement accounts for 2-5% of the facial lesions. CL lesions localized in the periocular region can easily be confused with various other diseases. The aim of this study was to examine the frequency of periocular involvement in CL in the Cukurova region of Turkey, as well as the clinical characteristics, diagnosis and methods of treatment of this disease. METHODS: Between December 1998 and December 2004, patients who were diagnosed with CL were evaluated prospectively with respect to periocular involvement. RESULTS: From the 2066 patients evaluated with CL, 2622 lesions were identified. In 59 (2.9%) of these patients, a total of 66 (2.5%) lesions were located in the periocular area. Thirty-two (48.5%) of these lesions were of the papular type, 15 (22.7%) the nodulo-ulcerative type, 10 (15.2%) the plaque type, and nine (13.6%) the nodular type. Dacryocystitis was identified in four patients with periocular involvement. Over the follow-up period, no ocular or periocular deformities or complications developed in these patients. CONCLUSION: Patients suspected of CL should be evaluated and treated early in the course of their disease to prevent any permanent ocular or periocular deformities. 相似文献
36.
37.
R Dixon AM Hughes K Nairn M Sellers JV Kemp RA Yates 《Cephalalgia : an international journal of headache》1998,18(7):468-475
Zolmitriptan (ZomigTM ) is a 5HT1B/1D agonist which has the ability to cross the intact blood-brain barrier to access central as well as peripheral receptors. Because of the potential for central nervous system side effects, this randomized, double-blind, placebo-controlled, 6-period crossover study evaluated the effects of 2.5 and 5 mg doses of zolmitriptan on psychomotor performance and investigated any pharmacodynamic or pharmacokinetic interaction with diazepam. Twelve healthy volunteers received the following "treatments" as single doses: zolmitriptan 2.5 mg, zolmitriptan 5 mg, diazepam 10 mg, zolmitriptan 2.5 mg+diazepam 10 mg, zolmitriptan 5 mg+diazepam 10 mg and placebo. Pre-dose and at 1, 4, 8, and 24 h post-dose, the following validated battery of psychomotor tests was performed: Bond-Lader visual analogue scales (calmness, contentedness, and alertness factors), critical flicker fusion test, choice reaction time (recognition, motor, and total reaction times), finger-tapping test, number cancellation test and digit symbol substitution test. Plasma concentrations of zolmitriptan, its active metabolite, and diazepam and its active metabolites were measured at the same timepoints. Zolmitriptan 2.5 and 5 mg had no effect on psychomotor function when given alone. In contrast, diazepam 10 mg had profound effects, consistent with its sedative properties, but there was no synergism on concomitant administration of either dose of zolmitriptan. Plasma concentrations of zolmitriptan, diazepam, and their respective active metabolites were similar when the two drugs were given alone or in combination. 相似文献
38.
B Fournier M Leclercq C Audigier-Petit R Letoublon R Got J Frot-Coutaz 《International journal for vitamin and nutrition research. Internationale Zeitschrift für Vitamin- und Ern?hrungsforschung. Journal international de vitaminologie et de nutrition》1987,57(2):145-150
Cow's milk has been shown to contain a protein complex which is able to bind vitamin K1 in a reversible manner. This binding property has been investigated by the celite method which consists in creating a dynamic equilibrium between the adsorbent, the celite and the protein complex for the ligand (vitamin K1). Based on competition experiment, the binding is specific and the vitamin K1 binding protein complex has a molecular weight equal to or higher than 7.5 X 10(2) KD. 相似文献
39.
40.
Tarek Sadek Hakim Mazouz Hedi Bahloul Roxana Oprisiu Najeh El Esper Isabelle El Esper Francis Boitte Michel Brazier Philippe Moriniere Albert Fournier 《Nephrology, dialysis, transplantation》2003,18(3):582-588
BACKGROUND: Sevelamer hydrochloride was recently proposed as a phosphate binder to prevent hypercalcaemia in place of calcium alkaline salts in dialysis patients. So far, it has been evaluated only in patients receiving calcitriol, without comparison with CaCO(3) alone, although the latter was found to be as effective as the combination of calcitriol and Al(OH)(3) in suppressing parathyroid hormone (PTH) without inducing hypercalcaemia and to have a better lowering effect on serum phosphate. Moreover, this bile salt binder may decrease serum 25-OH vitamin D. Therefore, we compared for 5 months two strategies for controlling moderate hyperparathyroidism: CaCO(3) alone vs sevelamer in conjunction with measures to increase calcium balance. METHODS: Forty-two patients were randomized: 21 continued their treatment with 4.8 g/day CaCO(3) and 21 were switched to sevelamer (initial dose: 2.4 g/day, increased to 4.4 g/day). Each month, when serum-corrected calcium decreased below 2.30 mmol/l, dialysate calcium was increased or alphacalcidol was given at each dialysis session, according to serum PO(4) levels. The following parameters were monitored: serum Ca, PO(4), bicarbonate and protein, weekly; and serum PTH, 25-OH vitamin D and total, LDL and HDL cholesterol monthly. RESULTS: Except for higher serum phosphate at month 1, lower serum bicarbonate at month 2 and lower LDL cholesterol at month 5 in the sevelamer group, no difference was found between the two groups. Compared with baseline levels, PTH increased and 25-OH vitamin D decreased significantly in both groups, these two parameters being inversely correlated. CONCLUSIONS: Given comparable control of plasma calcium, phosphate and 25-OH vitamin D, PTH control is comparable in both strategies. Sevelamer does not induce greater vitamin D depletion than CaCO(3). The transient decrease of serum bicarbonate after discontinuation of CaCO(3) in the sevelamer group suggests a less optimal prevention of acidosis. The sevelamer-induced decrease in LDL cholesterol gives this drug a potential advantage in cardiovascular prevention. 相似文献